EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tumor-specific CD8 + T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes

Elizabeth M Zawidzka, Luca Biavati, Amy Thomas, Claudio Zanettini, Luigi Marchionni, Robert Leone, Ivan Borrello

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-009367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Elizabeth M Zawidzka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Melanoma, Experimental, Immunotherapy, Adoptive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Cancer Center Core Grant, Kathryn Zugby Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy is now an integral aspect of cancer therapy. Strategies employing adoptive cell therapy (ACT) have seen the establishment of chimeric antigen receptor (CAR)-T cells using peripheral blood lymphocytes as well as tumor-infiltrating lymphocytes (TILs) with significant clinical results. The bone marrow (BM) is an immunological niche housing T cells with specificity for previously encountered antigens, including tumor-associated antigens from certain solid cancers. This study sought to improve our understanding of tumor-specific BM T cells in the context of solid tumors by comparing them with TILs, and to assess whether there is a rationale for using the BM as a source of T cells for ACT against solid malignancies.

Methods

We used the murine B16 melanoma model examining both the endogenous OVA-specific T cell response using an OVA-specific tetramer or examining the OVA-specific response with OVA-specific transgenic CD8+ (OT-1) T cells. Specifically, we compared baseline intrinsic properties of TILs or BM T cells from tumor-bearing mice and their changes following adoptive transfer in the tumor and bone marrow (as well as other compartments when indicated).

Results

In tumor-bearing mice, endogenous tumor-specific T cells could be detected in the BM early in the course of tumor progression and possessed a more stem-cell-like and memory phenotype in an unsupervised cluster analysis compared with TILs which appeared more exhausted. The BM and tumor microenvironments significantly impact the fate of T cells. Naïve OT-1 transferred T cells acquired an exhausted phenotype in the tumor but maintained a more memory-like phenotype in the BM with tumor progression. Importantly, in a competitive transfer experiment, BM T cells infiltrated the tumor more efficiently than TILs, displayed a higher polyfunctionality with interleukin-2, interferon-γ, tumor necrosis factor-α production and showed greater persistence compared with TILs.

Conclusions

T cells from the BM appear superior to TILs as a source of cells for cellular therapy. They possess a memory-enriched phenotype and exhibit improved effector function, greater persistence within a tumor-bearing host, and the capacity for increased tumor infiltration. These data provide a foundation for further exploring the BM as a source of tumor-specific T cells for ACT in solid malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingCD8-Positive T-LymphocytesMelanoma, ExperimentalImmunotherapy, AdoptiveBone MarrowBone Marrow CellsAnimalsMiceMice, Inbred C57BLCell Line, TumorMice, Transgenic

Stichwörter der Autor:innen

Adoptive cell therapy - ACTTumor infiltrating lymphocyte - TIL

Autor:innen und Institutionen

  • Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine School of Medicine, Baltimore, Maryland, USA.
  • Weill Cornell Medical College, New York, New York, USA.
  • Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine School of Medicine, Baltimore, Maryland, USA iborrello@tgmg.org.
  • Cancer Institute, Tampa General Hospital, Tampa, Florida, USA.

Förderung

  • NCI NIH HHS
  • Cancer Center Core Grant
  • Kathryn Zugby Foundation
  • WindMil Therapeutics

Zitieren

APA

Zawidzka, E. M., Biavati, L., Thomas, A., Zanettini, C., Marchionni, L., Leone, R., & Borrello, I. (2025). Tumor-specific CD8 + T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009367

Vancouver

Zawidzka EM, Biavati L, Thomas A, Zanettini C, Marchionni L, Leone R, et al. Tumor-specific CD8 + T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-009367

BibTeX
@article{Zawidzka2025,
  author = {Zawidzka, Elizabeth M and Biavati, Luca and Thomas, Amy and Zanettini, Claudio and Marchionni, Luigi and Leone, Robert and Borrello, Ivan},
  title = {Tumor-specific CD8 + T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-009367}
}
Kostenlos starten →